Akero Therapeutics, Inc. — Director's Dealing 2022

Dec 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2022-12-09

Reporting Person: Young Jonathan (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-09	Common Stock	A	19195	$0.00	Acquired	182449	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-09	Stock Option (Right to Buy)	$42.95	A	86379	Acquired	2032-12-08	Common Stock (86379)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000	Indirect
Common Stock	20000	Indirect
Common Stock	20000	Indirect

Footnotes

F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

F2: These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.